EBV BNRF1 (1238-1252)
The Epstein-Barr Virus major tegument protein BNRF1 epitope (1238-1252) is a common target of cytotoxic CD4+ T cells. Knowledge of the EBV epitopes can improve cellular immunotherapy.
Catalogue number crb1001669 Molecular Weight 1838.9 Sequence (one letter code)
Sequence (three letter code)
Purity >95% Storage -20°C References
Adhikary et al., (2020). The Epstein-Barr Virus Major Tegument Protein BNRF1 Is a Common Target of Cytotoxic CD4+ T Cells. J Virol., 94(15): e00284-20. PMID: 32461311.
Liechti and Roederer (2019). OMIP-060: 30-Parameter Flow Cytometry Panel to Assess T Cell Effector Functions and Regulatory T Cells. Cytometry A. PMID: 31334913.
Zhang et al (2012). How much of virus-specific CD8 T cell reactivity is detected with a peptide pool when compared to individual peptides? Viruses. PMID: 23202497.
Manufactured in: United Kingdom
Cellular immunotherapy is an effective treatment option against Epstein-Barr virus (EBV)-driven lymphoproliferation in recipients of hematopoietic stem cells. However, increasing the number of identified epitope targets will help improve the response rate and success. Viral tegument protein BNRF1 is a critical target in EBV inducing specific CD4+ T-cell responses. 18 epitopes within BNRF1 are known, including (1238-1252). BNRF1-specific CD4+ T cells are cytotoxic and limit EBV-driven B cell transformation. Work with EBV BNRF1 (1238-1252) epitope and others will help improve T cell immunotherapy and our understanding of host-virus interaction.